OmniAb (NASDAQ:OABI) versus OneMedNet (NASDAQ:ONMD) Financial Comparison

OmniAb (NASDAQ:OABIGet Free Report) and OneMedNet (NASDAQ:ONMDGet Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Risk & Volatility

OmniAb has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500. Comparatively, OneMedNet has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500.

Valuation and Earnings

This table compares OmniAb and OneMedNet’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OmniAb $59.08 million 10.84 -$22.33 million ($0.30) -18.37
OneMedNet N/A N/A $340,000.00 ($0.19) -4.73

OneMedNet has lower revenue, but higher earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than OneMedNet, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OmniAb and OneMedNet’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OmniAb -45.99% -8.88% -7.29%
OneMedNet N/A N/A -13.19%

Analyst Recommendations

This is a breakdown of current ratings and price targets for OmniAb and OneMedNet, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OmniAb 0 0 4 0 3.00
OneMedNet 0 0 0 0 N/A

OmniAb currently has a consensus target price of $8.75, indicating a potential upside of 58.80%. Given OmniAb’s higher possible upside, analysts clearly believe OmniAb is more favorable than OneMedNet.

Insider and Institutional Ownership

58.7% of OmniAb shares are held by institutional investors. Comparatively, 35.4% of OneMedNet shares are held by institutional investors. 7.0% of OmniAb shares are held by insiders. Comparatively, 45.7% of OneMedNet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

About OmniAb

(Get Free Report)

OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

About OneMedNet

(Get Free Report)

OneMedNet Corporation develops technology that focuses on accessing and sharing health data. It offers BEAM Medical Image Exchange & Management Suite, a solution that manages, exchanges, and shares medical images with patients, care providers, and hospitals. The company was founded in 2009 and is based in Eden Prairie, Minnesota with a development office in Vancouver, Canada.

Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.